New test predicts Alzheimer's timeline

Researchers at Columbia University found that combining a blood test measuring p-tau217 with genetic testing for the APOE4 gene can predict when high-risk patients will develop cognitive decline.

How the blood marker works

P-tau217 is a protein form that increases when Alzheimer's pathology develops. It can be measured in blood, making it a potential early warning signal sometimes before symptoms appear.

Genetic risk factor APOE4

People inherit different versions of the APOE gene. APOE4 is linked to higher Alzheimer's risk and earlier onset, though carrying it doesn't guarantee the disease will develop.

Study shows three to four year window

Patients with higher p-tau217 levels and one or more copies of APOE4 were likely to develop cognitive decline within three to four years, compared to those without these markers.

“the same p-tau217 level may mean different things in people with different genetic backgrounds.”

Early intervention could be key

Identifying people on a trajectory toward Alzheimer's before major symptoms appear could be valuable since interventions work best before substantial brain damage occurs.

Results vary by race and ethnicity

The strength of the relationship between the blood test, genetic risk, and Alzheimer's progression varied across study groups, suggesting the tools may not work equally for everyone.

“risk prediction is not one size fits all.”

Need for more diverse research

Experts say future studies must include more diverse populations to ensure these tools give accurate risk assessment for all patients without underestimating or overstating risk.